TG1N Stock Overview
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Armata Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.40 |
| 52 Week High | US$4.46 |
| 52 Week Low | US$0.93 |
| Beta | 0.70 |
| 1 Month Change | -29.41% |
| 3 Month Change | -32.96% |
| 1 Year Change | 65.52% |
| 3 Year Change | -32.96% |
| 5 Year Change | n/a |
| Change since IPO | -36.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| TG1N | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -19.5% | -1.2% | 1.7% |
| 1Y | 65.5% | -23.0% | 2.3% |
Return vs Industry: TG1N exceeded the German Biotechs industry which returned -22.4% over the past year.
Return vs Market: TG1N exceeded the German Market which returned 2.2% over the past year.
Price Volatility
| TG1N volatility | |
|---|---|
| TG1N Average Weekly Movement | 14.9% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: TG1N's share price has been volatile over the past 3 months.
Volatility Over Time: TG1N's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 66 | Deborah Birx | www.armatapharma.com |
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
Armata Pharmaceuticals, Inc. Fundamentals Summary
| TG1N fundamental statistics | |
|---|---|
| Market cap | €85.46m |
| Earnings (TTM) | -€64.52m |
| Revenue (TTM) | €4.23m |
20.0x
P/S Ratio-1.3x
P/E RatioIs TG1N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TG1N income statement (TTM) | |
|---|---|
| Revenue | US$4.53m |
| Cost of Revenue | US$33.77m |
| Gross Profit | -US$29.24m |
| Other Expenses | US$39.80m |
| Earnings | -US$69.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.91 |
| Gross Margin | -645.64% |
| Net Profit Margin | -1,524.51% |
| Debt/Equity Ratio | -256.7% |
How did TG1N perform over the long term?
See historical performance and comparison